nicotine has been researched along with Atherosclerotic Parkinsonism in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (25.00) | 18.7374 |
| 1990's | 5 (31.25) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chavez-Noriega, LE; Cosford, ND; Holsenback, H; Lloyd, GK; McDonald, IA; Menzaghi, F; Rao, TS; Reid, R; Sacaan, AI; Suto, CM; Urrutia, A; Vernier, JM; Washburn, MS; Whitten, JP | 1 |
| Ashraf, GM; Barreto, GE; Cabezas, R; Díaz, JE; Echeverria, V; González, J; Jurado-Coronel, JC; Loaiza, AE; Sahebkar, A | 1 |
| Ly, J; Mallela, A; Quik, M; Zhang, D | 1 |
| Shimohama, S | 1 |
| Bordia, T; Perez, XA; Quik, M | 1 |
| Erdmann, R | 1 |
| Corsini, GU; Fornai, F; Maggio, R; Racagni, G; Riva, M; Vaglini, F | 1 |
| Earl, CD; Ferger, B; Kuschinsky, K; Oertel, WH; Spratt, C; Teismann, P | 1 |
| Domino, EF; Ni, L; Zhang, H | 1 |
| Jeyarasasingam, G; Quik, M | 1 |
| Abin-Carriquiry, JA; Costa, G; Dajas, F | 1 |
| Kamel, D; Kay, TS; Krentz, L; Meshul, CK; Moore, C | 1 |
| Lisciani, R; Silvestrini, B | 1 |
| Alho, AM; Kirch, DG; Wyatt, RJ | 1 |
| Diamond, EL; Kessler, II | 1 |
| Bhargava, LP; Dandiya, PC | 1 |
4 review(s) available for nicotine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Amyloid beta-Peptides; Animals; Drug Synergism; Galantamine; Glutamic Acid; Motor Neurons; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinson Disease, Secondary; Phosphatidylinositol 3-Kinases; Rats; Receptors, Nicotinic; Rotenone; Signal Transduction; Spinal Cord | 2009 |
Nicotine as a potential neuroprotective agent for Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Humans; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Nicotinic; Signal Transduction; Smoking; Substantia Nigra | 2012 |
[Neuroleptics and nicotine].
Topics: Antipsychotic Agents; Brain; Dyskinesia, Drug-Induced; Humans; Nicotine; Parkinson Disease, Secondary; Receptors, Dopamine; Receptors, GABA; Receptors, Glutamate; Schizophrenia; Schizophrenic Psychology; Smoking | 1995 |
Hypothesis: a nicotine-dopamine interaction linking smoking with Parkinson's disease and tardive dyskinesia.
Topics: Dopamine; Drug Interactions; Dyskinesia, Drug-Induced; Humans; Nicotine; Parkinson Disease, Secondary; Smoking | 1988 |
12 other study(ies) available for nicotine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Conformationally restricted analogues of nicotine and anabasine.
Topics: Anabasine; Animals; Antiparkinson Agents; Calcium; Cell Line; Cholinergic Agonists; Drug Design; Humans; Macromolecular Substances; Molecular Conformation; Neurons; Nicotine; Parkinson Disease, Secondary; Piperidines; Pyridines; Recombinant Proteins; Structure-Activity Relationship; Transfection | 1998 |
(E)-Nicotinaldehyde O-Cinnamyloxime, a Nicotine Analog, Attenuates Neuronal Cells Death Against Rotenone-Induced Neurotoxicity.
Topics: Cell Death; Cell Line, Tumor; Cell Survival; Humans; Neurons; Neuroprotective Agents; Nicotine; Oxidative Stress; Parkinson Disease, Secondary; Reactive Oxygen Species; Rotenone | 2019 |
Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Cotinine; Data Interpretation, Statistical; Dyskinesia, Drug-Induced; Female; Levodopa; Male; MPTP Poisoning; Nicotine; Nicotinic Agonists; Parkinson Disease, Secondary; Saimiri | 2013 |
Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain-Derived Neurotrophic Factor; Cells, Cultured; Dopamine Uptake Inhibitors; Fibroblast Growth Factor 2; Male; Mesencephalon; Methamphetamine; Mice; Mice, Inbred C57BL; Neostriatum; Neuroprotective Agents; Neurotoxins; Nicotine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tyrosine 3-Monooxygenase | 1997 |
Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Cardiotonic Agents; Cyclic N-Oxides; Dopamine; Dopamine Agents; Drug Interactions; Free Radical Scavengers; Hydroxyl Radical; Locomotion; Male; Mice; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Nitrogen Oxides; Parkinson Disease, Secondary | 1998 |
Nicotine alone and in combination with L-DOPA methyl ester or the D(2) agonist N-0923 in MPTP-induced chronic hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agonists; Drug Interactions; Female; Levodopa; Macaca nemestrina; Motor Activity; Nicotine; Parkinson Disease, Secondary; Receptors, Dopamine D2; Rotation; Tetrahydronaphthalenes; Thiophenes | 1999 |
Nicotinic receptors and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Basal Ganglia; Dopamine Agents; Drug Interactions; Humans; Mesencephalon; Neuroprotective Agents; Nicotine; Parkinson Disease, Secondary; Receptors, Nicotinic; RNA, Messenger; Saimiri; Substantia Nigra; Tissue Distribution | 2000 |
Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chlorisondamine; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Injections, Subcutaneous; Male; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2001 |
Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Drug Administration Schedule; Drug Antagonism; Extracellular Space; Glutamic Acid; Immunohistochemistry; Male; Microdialysis; Microscopy, Electron; Motor Activity; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Synapses | 2002 |
Experimental data suggesting an adrenergic mechanism in the production of parkinsonian symptoms.
Topics: 5-Hydroxytryptophan; Animals; Atropine; Clonidine; Female; Fenclonine; Imipramine; Male; Mice; Mice, Inbred Strains; Nicotine; Oxotremorine; Parkinson Disease, Secondary; Phenoxybenzamine; Piloerection; Pyrilamine; Rabbits; Salivation; Sympathetic Nervous System; Trazodone; Tremor | 1976 |
Epidemiologic studies of Parkinson's disease. I. Smoking and Parkinson's disease: a survey and explanatory hypothesis.
Topics: Adolescent; Adult; Aged; Amines; Child; Facial Expression; Female; Humans; Male; Middle Aged; Movement Disorders; Nicotine; Parkinson Disease; Parkinson Disease, Secondary; Retrospective Studies; Smoking; Speech Disorders; Time Factors | 1971 |
The antiparkinsonian activity of monoamine oxidase inhibitors and other agents in rats and mice.
Topics: Animals; Dextroamphetamine; Diphenhydramine; Imipramine; Iproniazid; Isocarboxazid; Mice; Monoamine Oxidase Inhibitors; Nialamide; Nicotine; Nortropanes; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Perphenazine; Phenelzine; Physostigmine; Rats; Scopolamine; Sulfonic Acids; Tolazoline; Tremor; Tremorine; Trihexyphenidyl; Tryptamines | 1968 |